Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome
An erratum to this article was published (Arthritis Res Ther, 9 Jul 2024 ↗)
Authors' conclusion
Based on our results, RTX appears to be effective as rescue therapy in most patients with recurrent or progressive ASS-ILD unresponsive to conventional treatment. The use of RTX was well tolerated in the majority of patients.
Study context
- Population
- Patients with ASS-ILD and recurrent or ongoing progressive ILD despite GC and immunosuppressantsanalysed
- Participants
- 28 patients
- Exposure
- Pulmonary function before vs after rituximab (RTX) rescue therapy
- RTXn = 28
- Outcome
- Change in %pFVC and %pDLCO after RTX vs T0
- Follow-up
- 6 months
Methodological detailsmulticentre, observational, longitudinal
- Multicentre
- Observational
- Longitudinal
Main finding
As reported in the abstract
∆%pFVC
+6.29 %
95% CI −10.07 to 2.51; P = 0.002 compared to T0
RTX
∆%pDLCO
+6.15 %
95% CI −10.86 to −1.43P = 0.013
RTX
Observational data: associations, not effects.
Further findings
Prednisone dose
- Prednisone suspended
- 18%
- Significant reduction in median prednisone dose
Change in pulmonary function test (PFT) parameters from T0 (patients completing two years)
- ∆%pFVC
- +9.93% (95% CI: −15.61 to −4.25; p=0.002)
- ∆%pDLCO
- +7.66% (95% CI: −11.67 to −3.65; p<0.001)
- 24 completed one year and 22 two years of therapy
Oxygen therapy discontinued, among patients requiring it at start
- Oxygen therapy discontinued
- 33%
Safety
- Frequency of adverse events
- 28.5%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →